文献速递药物不良反应与药物警戒

磷霉素致17岁患者肝损伤一例

Fosfomycin-induced liver injury in a 17-year-old patient: A case report.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

本文报告一例既往健康的17岁男性在使用口服磷霉素后发生严重急性肝炎的病例。通过RUCAM评估得分为9分,提示磷霉素与肝损伤高度相关。经支持治疗和停用可疑药物后,患者肝功能逐渐恢复并完全康复。

要点

  • 磷霉素虽普遍耐受良好,但需警惕其罕见且可能严重的肝毒性。
  • 用药后出现肝损伤征象时应尽早识别并停用可疑药物。
  • 报告罕见不良反应有助于加强药物警戒和临床决策。

核心结论

  • 磷霉素可导致高度相关的严重药物性肝损伤,临床医生应保持警惕。
  • 早期识别和及时停用可疑药物对改善预后至关重要。

研究设计与样本

  • 单例病例报告:一名既往健康的17岁男性患者。

主要发现

  • 患者因肾绞痛相关排尿困难口服磷霉素500 mg每8小时一次,疗程7天,症状出现前15天内完成。
  • 实验室检查显示显著肝细胞损伤、凝血功能障碍、代谢性酸中毒、轻度肾前性急性肾损伤及炎症标志物升高。
  • 影像学显示肝大伴腹水,无胆道梗阻或血管异常。
  • 广泛评估排除了病毒性肝炎、自身免疫性肝病、Wilson病、缺血性肝炎、人畜共患感染及其他潜在肝毒性暴露。
  • 临床恶化出现低血压和少尿,入住ICU支持治疗4天后改善;RUCAM评分为9分,提示高度可能关联。

关键数值与推荐

  • RUCAM评分为9分,指示磷霉素与肝损伤高度可能相关。

临床怎么用

  • 使用磷霉素期间应监测肝损伤症状和肝功能指标。
  • 疑似磷霉素相关肝损伤时应立即停药并给予支持治疗。
  • 临床药师应关注并报告磷霉素罕见不良反应以加强药物警戒。

局限性

  • 单例病例报告,不能确定因果关系或估计发生率。
  • 无法排除其他未识别的潜在肝毒性因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe a case of severe acute hepatitis in an adolescent in whom fosfomycin was identified as the highly probable cause of drug-induced liver injury (DILI) and to highlight the potential hepatotoxicity of fosfomycin. SUMMARY: A previously healthy 17-year-old male presented with nausea, vomiting, fever, and progressive epigastric pain over 3 days, accompanied by fatigue and malaise. Laboratory testing revealed marked hepatocellular injury, coagulopathy, metabolic acidosis, mild pre-renal acute kidney injury, and elevated inflammatory markers. Imaging demonstrated hepatomegaly with ascites, without biliary obstruction or vascular abnormalities. Extensive evaluation excluded viral hepatitis, autoimmune liver disease, Wilson's disease, ischemic hepatitis, zoonotic infections, and other potential hepatotoxic exposures. Within the 15 days before symptom onset, the patient had completed a 7-day course of oral fosfomycin 500 mg every 8 hours for renal colic-associated dysuria, with no other medications linked to liver injury. Clinical deterioration with hypotension and oliguria required admission to the intensive care unit, where the patient improved with supportive management during a 4-day stay. Using the Roussel-Uclaf Causality Assessment Method (RUCAM), the score was 9, indicating a highly probable association between fosfomycin and the liver injury. Levels of liver enzymes gradually normalized, and the patient was discharged with full recovery. CONCLUSION: Although fosfomycin is widely used and generally well tolerated, clinicians should remain vigilant for this rare but potentially serious adverse effect. Early recognition and prompt discontinuation of the suspected agent are essential. Reporting uncommon adverse reactions helps strengthen pharmacovigilance and supports safer therapeutic decision-making.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Palazón Gonzálvez E, Nájera Pérez MD, Alegría Samper R, et al. Fosfomycin-induced liver injury in a 17-year-old patient: A case report. Am J Health Syst Pharm. 2026. PMID: 42261098. doi:10.1093/ajhp/zxag162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。